Wall Street brokerages expect that FibroGen Inc (NASDAQ:FGEN) will report sales of $45.37 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for FibroGen’s earnings, with the lowest sales estimate coming in at $37.64 million and the highest estimate coming in at $57.03 million. FibroGen reported sales of $31.91 million in the same quarter last year, which indicates a positive year over year growth rate of 42.2%. The firm is expected to announce its next quarterly earnings results on Wednesday, March 7th.
On average, analysts expect that FibroGen will report full year sales of $45.37 million for the current year, with estimates ranging from $120.80 million to $140.19 million. For the next fiscal year, analysts anticipate that the firm will post sales of $229.55 million per share, with estimates ranging from $207.00 million to $248.35 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for FibroGen.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.13). FibroGen had a negative return on equity of 47.36% and a negative net margin of 120.00%.
FibroGen (NASDAQ FGEN) traded up $0.55 during trading hours on Friday, hitting $47.85. 1,179,545 shares of the stock traded hands, compared to its average volume of 578,534. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83. The stock has a market cap of $3,980.00, a price-to-earnings ratio of -23.57 and a beta of 1.55. FibroGen has a 52-week low of $21.05 and a 52-week high of $60.15.
In related news, CEO Thomas B. Neff sold 38,636 shares of the business’s stock in a transaction on Tuesday, October 31st. The shares were sold at an average price of $56.13, for a total value of $2,168,638.68. Following the completion of the sale, the chief executive officer now owns 3,144,573 shares of the company’s stock, valued at approximately $176,504,882.49. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the business’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $46.65, for a total transaction of $93,300.00. Following the completion of the sale, the director now directly owns 24,000 shares of the company’s stock, valued at approximately $1,119,600. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 295,346 shares of company stock valued at $14,152,764. Insiders own 13.60% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Quantbot Technologies LP purchased a new stake in FibroGen in the 2nd quarter worth $128,000. Bank of Montreal Can increased its holdings in FibroGen by 2,097.2% in the 4th quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 3,041 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in FibroGen by 15.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after acquiring an additional 696 shares in the last quarter. Amalgamated Bank purchased a new stake in FibroGen in the 2nd quarter worth $237,000. Finally, Oppenheimer Asset Management Inc. increased its holdings in FibroGen by 112.6% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock worth $237,000 after acquiring an additional 2,336 shares in the last quarter. 57.23% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Analysts Expect FibroGen Inc (FGEN) Will Post Quarterly Sales of $45.37 Million” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/20/analysts-expect-fibrogen-inc-fgen-will-post-quarterly-sales-of-45-37-million.html.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.